Peripheral Arterial Disease Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Peripheral Arterial Disease Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including Peripheral Arterial Disease clinical trials and nonclinical stage products. It also covers the Peripheral Arterial Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral Arterial Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Peripheral Arterial Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Peripheral Arterial Disease Pipeline Report
• In November 2024:- CSL Behring- A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis
• In November 2024:- Eli Lilly and Company- The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
• DelveInsight's Peripheral Arterial Disease pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Peripheral Arterial Disease treatment.
• The leading Peripheral Arterial Disease Companies such as Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
• Promising Peripheral Arterial Disease Therapies such as Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temsirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others

Stay ahead with the most recent pipeline outlook for Peripheral Arterial Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peripheral Arterial Disease Treatment Drugs- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Arterial Disease Emerging Drugs Profile
• Semaglutide: Novo Nordisk
Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

• VM202: Helixmith
VM202 is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith's non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Peripheral Artery Disease.

• Revacept: AdvanceCor
Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

Explore groundbreaking therapies and clinical trials in the Peripheral Arterial Disease Pipeline. Access DelveInsight's detailed report now! @ New Peripheral Arterial Disease Drugs- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Peripheral Arterial Disease Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Peripheral Arterial Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peripheral Arterial Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral Arterial Disease Pipeline Report
• Coverage- Global
• Peripheral Arterial Disease Companies- Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
• Peripheral Arterial Disease Therapies- Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temsirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others
• Peripheral Arterial Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peripheral Arterial Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral Arterial Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Peripheral Arterial Disease Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Peripheral Arterial Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral Arterial Disease - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral Arterial Disease Collaboration Deals
9. Late Stage Products (Phase III)
10. Semaglutide: Novo Nordisk
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VM202: Helixmith
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. Revacept: AdvanceCor
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Peripheral Arterial Disease Key Companies
20. Peripheral Arterial Disease Key Products
21. Peripheral Arterial Disease Unmet Needs
22. Peripheral Arterial Disease Market Drivers and Barriers
23. Peripheral Arterial Disease Future Perspectives and Conclusion
24. Peripheral Arterial Disease Analyst Views
25. Peripheral Arterial Disease Key Companies
26. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.